Patient 2
A 3-year-old male with CD33+ AML received upfront therapy on AAML1031
Arm B (bortezomib arm), and relapsed with a scalp chloroma seven months
post-diagnosis. He was re-induced (Table 1), but following re-induction
a BMBA demonstrated 35% blasts. He then received clofarabine,
topotecan, thiotepa, and vinorelbine, and his MRD decreased to 1%. He
underwent unrelated donor peripheral stem cell transplant (PSCT)
followed by azacytidine for nine cycles before developing a maxillary
sinus chloroma and 33% marrow involvement with CD33+ myeloid blasts.
This second relapse prompted the decision to pursue GO.
A pre-GO ECHO showed normal LVEF of 60% and LVSF of 31% (Figure 1). He
received GO (3 mg/m2/dose) on days 1, 4, and 8 with
concurrent radiotherapy for the chloroma. BMBA on day 11 showed
hypocellularity without leukemic blasts. He received two additional
doses of GO on days 15 and 18 for 15mg/m2 total. He
then developed respiratory distress, hypotension, altered mental status,
and a distended abdomen requiring transfer to the intensive care unit
(ICU) while afebrile with negative blood cultures. An ECHO showed a
severely diminished LVEF of 21%, LVSF of 12%, and mild LV dilation. An
abdominal ultrasound (AUS) showed hepatomegaly but normal portal venous
flow. Labwork showed a BNP of 6373 pg/mL and a bilirubin that peaked at
2.9 mg/dL. He was started on dobutamine, milrinone, and epinephrine for
cardiogenic shock. His epinephrine and dobutamine were stopped after 2
days, milrinone was stopped after 14 days, and he initiated enalapril
and spironolactone. His LVEF improved to 55%, and LVSF to 29% within
12 days of the ICU transfer. A BMBA two months post-GO remained MRD
negative, and an ECHO three months post-GO showed stable LV function.
As a bridge to a second SCT, he received a cycle of decitabine.
4 months following GO, he underwent BMT. On day +16 he developed
hepatomegaly and a new cardiac gallop; ECHO showed a decrease in LVEF to
45% and LVSF to 25%, his BNP was 8167pg/ml, and he was transferred to
the ICU where furosemide and milrinone were started. AUS showed
hepatomegaly with normal flow in the portal vein. Five days later,
milrinone was stopped and within 1 week his BNP trended down to 396 and
his LVEF and LVSF normalized. 50 days post-BMT an ECHO and BNP were
repeated and remained normal. Unfortunately, 21 months post-BMT, he had
a bone marrow/extramedullary relapse and died 3 months later.
DISCUSSION
We present vignettes of two pediatric patients with r/r AML who
developed acute LV dysfunction following 15-18mg/m2 of
fractioned GO monotherapy, suggesting a potential relationship between
GO and cardiotoxicity in pre-treated AML patients. Both patients had
significant prior anthracycline exposure but low-normal to normal
cardiac function before GO administration. Their cardiac dysfunction was
characterized by severely decreased systolic and diastolic function,
elevated BNPs, and improvement with medical therapy.
Patient 2 was critically ill without alternative clinical explanation
when LVSD was identified while Patient 1 was initially asymptomatic,
suggesting the utility of routine ECHO monitoring in patients with AML
receiving GO-monotherapy at these doses. Both patients achieved
remission following three 3mg/m2 doses of GO,
tolerated full-intensity SCT, did not develop SOS, and maintained
post-SCT remissions for 9 months and counting for Patient 1, and 21
months for Patient 2. Given that fractionation was hypothesized to
reduce toxicity from GO, it is important to note that the cardiac
toxicity encountered at doses of 15-18mg/m2 was not
prevented by fractionation, although SOS did not occur and toxicity did
not preclude SCT. While cardiotoxicity is not commonly described with
GO, this and prior reports of worsening LVSF following
GO2,5 suggest the need for cardiac surveillance
following GO administration. Future studies evaluating cardiotoxicity
following GO may deepen our understanding of this clinically important
toxicity and guide optimal monitoring strategies for these patients.
ACNKOWLEDGEMENTS
We would like to thank all that contributed to and supported this
project. KM reviewed the medical histories, wrote and revised the
manuscript, created the table and figure. KG compiled echocardiogram
data. KG, KO, AS, and BO provided critical revisions to the manuscript.
RA conceptualized the project, provided guidance on the development of
the manuscript, and provided revisions. No authors have conflicts of
interest to disclose.
CITATIONS
1. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab Ozogamicin in
Children and Adolescents With De Novo Acute Myeloid Leukemia Improves
Event-Free Survival by Reducing Relapse Risk: Results From the
Randomized Phase III Children’s Oncology Group Trial AAML0531. J
Clin Oncol . 2014;32(27):3021-3032. doi:10.1200/JCO.2014.55.3628
2. Zwaan CM, Reinhardt D, Zimmerman M, et al. Salvage treatment for
children with refractory first or second relapse of acute myeloid
leukaemia with gemtuzumab ozogamicin: results of a phase II study.Br J Haematol . 2010;148(5):768-776.
doi:10.1111/j.1365-2141.2009.08011.x
3. Arceci RJ. Safety and efficacy of gemtuzumab ozogamicin in pediatric
patients with advanced CD33+ acute myeloid leukemia. Blood .
2005;106(4):1183-1188. doi:10.1182/blood-2004-10-3821
4. Brethon B, Auvrignon A, Galambrun C, et al. Efficacy and tolerability
of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676,
Mylotarg®) in children with relapsed/refractory myeloid leukemia.BMC Cancer . 2006;6(1):172. doi:10.1186/1471-2407-6-172
5. Niktoreh N, Lerius B, Zimmermann M, et al. Gemtuzumab ozogamicin in
children with relapsed or refractory acute myeloid leukemia: a report by
Berlin-Frankfurt-Münster study group. Haematologica .
2019;104(1):120-127. doi:10.3324/haematol.2018.191841
6. Brethon B, Yakouben K, Oudot C, et al. Efficacy of fractionated
gemtuzumab ozogamicin combined with cytarabine in advanced childhood
myeloid leukaemia. Br J Haematol . Published online August 2008.
doi:10.1111/j.1365-2141.2008.07370.x
7. Liu AP-Y, Leung AW-K, Cheuk DK-L, Lee V, Ha S-Y. Gemtuzumab
Ozogamicin Containing Chemotherapy for Relapsed or Refractory Acute
Myeloid Leukemia (AML) in Children: J Pediatr Hematol Oncol .
2018;40(2):163-168. doi:10.1097/MPH.0000000000001010
8. Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and Efficacy of
Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric
Acute Myeloid Leukemia: A Report From The Children’s Oncology Group.J Clin Oncol . 2008;26(14):2390-2395. doi:10.1200/JCO.2007.13.0096
9. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the
efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with
CD33-positive acute myeloid leukemia in first recurrence. Cancer .
2005;104(7):1442-1452. doi:10.1002/cncr.21326
10. Taksin A-L, Legrand O, Raffoux E, et al. High efficacy and safety
profile of fractionated doses of Mylotarg as induction therapy in
patients with relapsed acute myeloblastic leukemia: a prospective study
of the alfa group. Leukemia . 2007;21(1):66-71.
doi:10.1038/sj.leu.2404434
TABLE 1 Legend: